For research use only. Not for therapeutic Use.
T2AA (Cat No.: I011012) is a small-molecule inhibitor targeting the transcription factor TCF7L2, a key regulator in the Wnt/β-catenin signaling pathway. By disrupting TCF7L2–β-catenin interactions, T2AA inhibits Wnt-driven transcription, making it a valuable tool in cancer research. It has been studied for its potential in treating colorectal cancer and other malignancies where Wnt signaling is dysregulated. T2AA also plays a role in metabolic disease research due to TCF7L2’s involvement in glucose homeostasis and insulin regulation, highlighting its therapeutic relevance beyond oncology.
| CAS Number | 1380782-27-3 |
| Synonyms | (βS)-β-Amino-4-(4-hydroxyphenoxy)-3,5-diiodobenzenpropanol |
| Molecular Formula | C15H15I2NO3 |
| Purity | ≥95% |
| Target | DNA/RNA Synthesis |
| Solubility | Soluble to 100 mM in DMSO |
| Storage | Store at -20C |
| IUPAC Name | 4-[4-[(2S)-2-amino-3-hydroxypropyl]-2,6-diiodophenoxy]phenol |
| InChI | 1S/C15H15I2NO3/c16-13-6-9(5-10(18)8-19)7-14(17)15(13)21-12-3-1-11(20)2-4-12/h1-4,6-7,10,19-20H,5,8,18H2/t10-/m0/s1 |
| InChIKey | NKOSKXJRVWVXRI-JTQLQIEISA-N |
| SMILES | C1=CC(=CC=C1O)OC2=C(C=C(C=C2I)C[C@@H](CO)N)I |
